Skip to main
  1. Stocks
  2. Biomea Fusion Inc
  3. Forecast
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion is attractive because icovamenib appears to be a differentiated, disease-modifying asset with confirmatory Phase 2 programs already underway: COVALENT-211 enrolled 64 participants across 18 sites and is due to report 26-week data in 1Q27, while COVALENT-212 is expected to finish enrollment by YE26 with topline data in 2Q27. The company also has early but encouraging breadth from BMF-650, which delivered 1.5% to 3.2% mean day-29 weight loss across active cohorts and 6.1% in the confined cohort, alongside mostly mild or moderate adverse events and no severe, serious, or treatment-related discontinuations, supporting a potentially partnerable oral GLP-1 profile. Taken together, the pipeline offers two shots on goal in high-need metabolic markets, with mechanistic data, tolerability, and upcoming readouts providing multiple catalysts that could de-risk development and broaden strategic interest.

Bears say

Biomea Fusion is viewed negatively because its lead programs, icovamenib and BMF-650, remain early and unproven, with efficacy and safety needing confirmation in larger, controlled trials after only encouraging preclinical and short-course Phase 2 signals. The apparent A1c benefit may be vulnerable to small subgroup effects, post-hoc analysis, and non-monotonic dose-response, while later studies could reveal weaker durability or hepatic and off-target risks. Financially, the company is still generating operating losses, is not expected to be profitable before commercialization, and may need additional capital with potentially dilutive impact, all while facing intense competition in diabetes and obesity markets.

BMEA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

BMEA Analyst Forecast & Price Prediction

Get the latest BMEA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BMEA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Strong Buy based on their latest research and market trends.

According to 5 analysts, BMEA has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


BMEA Analyst Forecast & Price Prediction

Get the latest BMEA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BMEA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BMEA stock data and trends